Company No: 10947371 (England and Wales)

Contents

• Balance Sheet
• Notes to the Financial Statements

		2025		2024
		£		£
Fixed assets		1,447		2,160
Current assets		231,185		192,849
Creditors: amounts falling due within one year		( 43,679)		( 56,631)
Net current assets		187,506		136,218
Total assets less current liabilities		188,953		138,378
Accruals and deferred income		( 1,946)		( 1,871)
Net assets		187,007		136,507
Capital and reserves		187,007		136,507

For the financial year ending 30 September 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
• The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements;
• These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime;
• These financial statements have been delivered in accordance with the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Bristol Thoracic Imaging Limited (registered number: 10947371) were approved and authorised for issue by the Board of Directors on 18 September 2026 and were signed on its behalf by:

Dr Anthony Edey Director

1. Company information

The Company is a private company limited by shares and is incorporated in the United Kingdom and registered in England and Wales (Company no. 10947371). The address of its registered office is Goodwood House, Blackbrook Park Avenue, Taunton, TA1 2PX, United Kingdom.

2. Employees

	2025		2024
	Number		Number
Monthly average number of persons employed by the Company during the financial year, including directors	2		2

3. Directors’ benefits: advances, credit and guarantees

Advances

At 01 October 2024, the balance owed by the director was £44,064. During the year, £2,503 was advanced to the director, and £1,577 was repaid by the director. At 30 September 2025 the balance owed to the company by the director was £44,990.

At 01 October 2023, the balance owed by the director was £362. During the year, £44,208 was advanced to the director, and £506 was repaid by the director. At 30 November 2024, the balance owed by the the director was £44,064.

The Directors loan account is repayable on demand and interest has been charged on overdrawn balances exceeding £10,000 at the official HMRC rates.

4. Change in accounting framework

During the year the company became eligible to apply the micro-entities regime and has prepared these financial statements in accordance with FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime.

The comparative figures for the previous year have been restated where necessary to comply with the recognition and measurement requirements of FRS 105. Any resulting adjustments have been reflected in opening reserves at the date of transition.

The transition from FRS 102 Section 1A to FRS 105 did not result in any material adjustments to the company's reported financial position or results.